Pharmaceutical companies have promoted the overprescription of opioid painkillers in order to increase their profits.
NOT BSTOTAL BS
NOT BS — Verdict: True
Verified by Lenz ·
The Short Version
Extensive evidence shows several opioid manufacturers promoted higher prescribing to increase sales and profits. That evidence includes Purdue Pharma’s federal guilty plea, congressional investigations, and peer-reviewed studies linking industry marketing and physician payments to increased opioid prescribing and overdose harm. The wording is broad, but the central claim is well supported.
Caveats
The strongest direct evidence concerns opioid manufacturers, especially Purdue Pharma; the claim should not be read as applying equally to every pharmaceutical company.
"Overprescription" is partly a clinical and policy judgment, though the evidence shows companies encouraged prescribing beyond safe, well-supported use.
Industry marketing was a major driver, but not the only one; prescriber behavior, regulatory failures, and broader health-system factors also contributed to the opioid crisis.